Year Established: 1668
Revenues: $15,828 (+13%)
Net Income: $1,716 (+41%)
R&D: $2,081 (+11%)
TOP SELLING DRUGS
|Glucophage||type 2 diabetes||$409||-14%|
In Merck KGaA’s Healthcare division, it discovers, develops and manufactures prescription medicines used to treat cancer, multiple sclerosis, and infertility, among other things, as well as over-the-counter pharmaceutical products for colds and pain.
The Healthcare business sector comprises four businesses: Biopharma, Consumer Health, Biosimilars, and Allergopharma. In 2016, Healthcare generated 45% of group sales, or $15.8 billion. Europe and North America generated 60% of Healthcare’s sales in 2016, while in recent years the company has steadily expanded its presence in growth markets. In 2016, Asia-Pacific and Latin America accounted for 33% of sales.
Biopharma is the largest of the Healthcare businesses and operates in four franchises. During the year, new data on Rebif, Biopharma’s top-selling drug and leading multiple sclerosis (MS) therapy were presented at both the American Academy of Neurology’s (AAN) Annual Meeting in April 2016 and the Congress of the European Academy of Neurology (EAN) in May 2016.
In June 2016, the company reached a major regulatory milestone with the submission for registration of cladribine tablets to the European Medicines Agency (EMA). The company says that cladribine tablets, if approved, could lead to high and sustained efficacy through selective modulation of B and T cells resulting in lasting resolution of inflammation.
Erbitux (cetuximab) remains the second best-selling drug in the portfolio of the Biopharma business and is the company’s flagship product in oncology. In April 2016 Merck reached a major milestone regarding its expansion in growth markets with the positive results of the pivotal Chinese Phase III TAILOR study.
Also, through a strategic alliance with Pfizer, the company continued to make progress in the development and envisaged commercialization of avelumab, an investigational fully human anti-programmed death-ligand 1 (PD-L1) antibody.
The positive results from JAVELIN Merkel 200, the pivotal Phase II study in patients with metastatic Merkel cell carcinoma (MCC) treated with avelumab in second or subsequent lines of therapy, were presented at the American Society of Clinical Oncology (ASCO) 2016 annual meeting.
In terms of facility expansions, Merck KGaA continued to invest in its manufacturing network across the globe. In 2016, it completed the construction of a new facility in Nantong, China and expanded a plant in Rio de Janeiro, Brazil, as well.
The company also unveiled plans to invest more than €50 million in a new packaging center of excellence at its pharmaceutical manufacturing site in Darmstadt while also completing the expansion of its plant in Tres Cantos, Spain. In Aubonne, Switzerland, it pushed forward with the construction of a new packaging center there as well.
In the U.S., the company revealed plans for a new $115 million hub in Burlington, MA, that will serve as a major center of operations for the North American Life Science business. The new campus will also house an M Lab Collaboration Center.